SEC Form 4 · accession 0001179022-18-000051
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harold H. Shlevin
Officer — Chief Operating Officer
Period of report
Jun 12, 2018
Accepted (ET)
Jun 14, 2018 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 12, 2018 | S | 12,780 | $6.50 | D | 5,374 | D | |
| Common Stock | Jun 13, 2018 | M | 25,544 | $0.00 | A | 30,918 | D | |
| Common StockF3 | Jun 13, 2018 | S | 30,918 | $7.7921 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $3.45 | Jun 13, 2018 | M | 25,544 | D | — | Jan 29, 2025 | Common Stock | 25,544 | 12,456 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018.
- F2The options vested as follows: 25% on January 29, 2015, the grant date, with the remainder vesting ratably on a monthly basis over a three year period.
- F3The shares were sold in multiple transactions at prices ranging from $6.52 to $8.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.